Орунгал (Itraconazole) is generally applied in managing conditions where symptoms may intensify temporarily due to a widespread, deep-seated, or chronic infection. This use is relevant for easing symptoms related to systemic imbalance and symptoms that interfere with daily functioning.

This medication is commonly used across conditions presenting with acute episodes related to serious, deep-seated infections such as Blastomycosis, Histoplasmosis, and specific forms of Aspergillosis. This use is also relevant in clinical settings that involve acute or unstable symptom patterns, such as supportive symptom management for prophylaxis in high-risk groups, including those with compromised immunity. The medication is also applied for extensive superficial infections like severe Onychomycosis.

This supportive use assists with maintaining functional stability and offers symptomatic relief that helps patients cope more steadily with difficult episodes. The medication helps address symptom clusters that include persistent fever, chills, malaise, and unexplained weight loss, which are symptoms related to systemic imbalance.

“The primary benefit contributes to improved day-to-day comfort during symptomatic periods and supports general well-being.”

---

Quick Fact: Support for Systemic Imbalance The drug helps address symptom clusters that include persistent fever, chills, malaise, and unexplained weight loss, which are symptoms related to systemic imbalance.

---

Eligibility and Contraindications for Орунгал (Itraconazole)

Official regulatory documents define strict limitations on who can use Itraconazole. This medicine is absolutely contraindicated in patients with or who have a history of congestive heart failure (CHF) or other evidence of ventricular dysfunction, especially for non-life-threatening indications.

Classification	Population or Condition
Absolute Contraindication	Congestive Heart Failure (CHF), Hypersensitivity to Itraconazole.
	Pregnancy (except for life-threatening systemic mycoses).
	Concurrent use with specific contraindicated drugs.
Not Established / Not Recommended	Pediatric population (children) for non-life-threatening infections.
	Lactating/breastfeeding women.
Conditional Use / Caution	Patients with hepatic impairment or renal impairment.
	Older adults (geriatric population).
	Patients with cardiac risk factors or low gastric acidity (achlorhydria).

The safety and efficacy of the capsules are not established for most uses in children. Use in pregnancy is strictly contraindicated for treating non-life-threatening conditions, and women of childbearing potential must use effective contraception during treatment. Patients with existing liver or kidney impairment, or those with other risk factors for CHF, are permitted use only with caution and close monitoring, as defined by regulatory bodies.

Itraconazole (the active substance in Орунгал) is a potent inhibitor of cytochrome P450 3A4 (CYP3A4), a major enzyme responsible for metabolizing many other medications in the liver. Concomitant use with drugs also metabolized by CYP3A4 can lead to significantly increased plasma concentrations of the other drug, potentially causing serious or life-threatening adverse effects, including heart rhythm abnormalities like QT prolongation and Torsades de Pointes.

Contraindicated Medications

The following are examples of drug classes and specific agents that should not be taken with itraconazole due to the risk of severe drug interactions:

• Certain Antihistamines: Astemizole, Terfenadine
• Certain Lipid-Lowering Agents: Lovastatin, Simvastatin
• Gastrointestinal Motility Agents: Cisapride
• Certain Sedatives/Hypnotics: Midazolam (oral), Triazolam
• Antiarrhythmics: Dofetilide, Quinidine
• Ergot Alkaloids: Dihydroergotamine, Ergotamine, Methylergometrine

Other Significant Interactions

Itraconazole may require dose adjustments or careful monitoring when used with numerous other drugs, including certain oral anticoagulants, immunosuppressants (like Cyclosporine, Tacrolimus, Sirolimus), calcium channel blockers, HIV protease inhibitors, and some chemotherapy agents.

Conversely, drugs that induce the CYP3A4 enzyme, such as Rifampin, Phenytoin, and certain anticonvulsants, can significantly decrease the level of itraconazole in the blood, leading to reduced effectiveness. Medications that reduce stomach acid (e.g., antacids, proton pump inhibitors, H2-receptor antagonists) can also reduce itraconazole absorption. It is critical to discuss all concurrent medications and supplements with a healthcare provider before starting or stopping any treatment.

Core Mechanism: Inhibiting Fungal Ergosterol Synthesis

Орунгал (Itraconazole) acts as an inhibitor of the fungal enzyme lanosterol 14alpha-demethylase (14alpha-LDM), which is essential for the ergosterol biosynthesis pathway. This specific blockage prevents the conversion of lanosterol into ergosterol, the primary sterol component of the fungal cell membrane. The process leads to the accumulation of toxic 14-methylated sterols and subsequent alteration of the fungal cell membrane's structural integrity.

Modulating Mammalian Proliferation Pathways

Beyond its primary antifungal role, the drug engages secondary mechanisms by acting on certain mammalian targets, notably by inhibiting Voltage-Dependent Anion Channel 1 (VDAC1) and modulating the Hedgehog (Hh) signaling pathway. This interference leads to the suppression of cell growth signals, contributing to a reduction in endothelial cell proliferation and migration.

Mechanistic Scope and Physiological Constraints

The drug's targets and interactions are predominantly peripheral in scope, operating on systemic fungal and accessible mammalian cellular targets. Its limited ability to cross the blood-brain barrier acts as a constraint, which defines the systemic distribution and reach of the mechanism, particularly where CNS penetration is limited.

Орунгал (Itraconazole) is a systemic antifungal agent administered via the oral route (capsules or solution) or intravenously (IV) by infusion. Administration procedures are strictly formulation-dependent due to significant differences in drug absorption.

Administration Requirements

Form	Timing Relative to Food	Dosage Equivalence
Capsules	Must be taken immediately after a full meal to maximize absorption.	Not interchangeable with Solution
Oral Solution	Must be taken on an empty stomach (refrain from eating for at least one hour afterward).	Not interchangeable with Capsules

For many systemic infections, the usage protocol begins with a loading dose of 200 mg administered twice daily for the first three days. This is followed by a maintenance dose of 200 mg once daily, which may be increased up to 400 mg daily, given in divided doses. A distinct pulse dosing regimen is used for conditions like onychomycosis, involving 200 mg twice daily for one week, followed by a three-week drug-free period, repeated for a second course.

The IV infusion must be administered over 60 minutes using a dedicated in-line filter, and its use is typically limited to a maximum of 14 days. Dose consideration is required for specific patient populations; notably, the IV formulation is contraindicated in patients with severe renal impairment.

Research Evidence / Overview of Studies for Орунгал

Evidence for Treating Severe Systemic Fungal Infections

Research examining Орунгал (Itraconazole) for severe systemic infections, such as Blastomycosis, Histoplasmosis, and Aspergillosis, was evaluated in clinical trials and observational studies. These studies primarily focused on populations of adults diagnosed with deep-seated or widespread fungal diseases. Outcomes monitored in these research settings included measurements of fungal clearance and overall clinical responses categorized by objective criteria.

The findings describe patterns observed in these studies where researchers monitored how symptoms evolved in the observed populations. Research related to systemic mycoses often stems from studies conducted during the drug's initial development. A key research limitation is that the results apply only to the populations studied, and the variable systemic absorption of the capsule form complicates the uniform interpretation of findings.

Evidence for Preventing Invasive Fungal Infections (Prophylaxis)

Орунгал has been studied in research exploring the prevention (prophylaxis) of invasive fungal infections (IFI) in high-risk, immunocompromised adult patients. This research landscape is largely composed of meta-analyses and randomized controlled trials (RCTs). Studies explored outcomes related to physical discomfort and acute changes by monitoring the incidence of confirmed IFI. Findings describe patterns observed in some studies that measured a lower incidence of IFI in the group receiving specific formulations, such as the oral solution. Follow-up durations were limited, often covering only the short-term high-risk period, meaning that long-term effects are not fully established.

Evidence for Extensive Superficial Infections (Onychomycosis)

Itraconazole was studied for extensive superficial fungal infections, such as severe Onychomycosis, primarily through randomized controlled trials (RCTs) involving non-immunocompromised adults. Research examined the rates of mycological cure and clinical response of the affected nail or skin tissue. The findings describe group patterns related to clinical and mycological response measurements reported in the observed populations. Study results required long-term observation (e.g., six months or more after treatment) to accurately assess the final clinical status.

Key Studies & References

1. Itraconazole (StatPearls - NIH National Library of Medicine)

Common questions about Орунгал (FAQ)

Q: What is Орунгал?

A: Орунгал (itraconazole) is a medication that belongs to the class of triazole antifungals. It is used in the treatment of various fungal infections.

Q: How does Орунгал work?

A: Орунгал is thought to exert its antifungal effects by interfering with the fungal cell membrane's ability to synthesize ergosterol, an essential component for the fungus to grow and survive.

Q: What is the recommended dosage for Орунгал?

A: The appropriate dosage and duration of treatment with Орунгал vary significantly depending on the specific type of fungal infection being treated and the patient's individual health status. A healthcare provider must determine the correct regimen. It is important to strictly follow the dosing instructions provided by a qualified medical professional.

Q: What are the common side effects of Орунгал?

A: The most frequently reported side effects associated with Орунгал include gastrointestinal issues such as nausea and abdominal pain. Additionally, some patients may experience headaches or changes in liver enzyme levels. This is not an exhaustive list, and any unexpected or severe reactions should be reported to a doctor.

Q: Can Орунгал interact with other medications?

A: Yes, Орунгал has the potential to interact with a wide range of other prescription and non-prescription medications, including certain heart medications, statins, and anti-seizure drugs. These interactions can affect the safety and effectiveness of either Орунгал or the other medication. Patients should provide their healthcare provider with a complete list of all current medications, supplements, and herbal products.

Q: Is Орунгал safe to take during pregnancy?

A: Орунгал is generally not recommended for use during pregnancy, particularly during the first trimester, due to potential risks to the fetus. The decision to use this medication in pregnant individuals requires a careful assessment of the potential benefits versus the risks. This discussion must occur with a healthcare professional.

Q: What should I do if I miss a dose of Орунгал?

A: If a dose is missed, individuals should consult the specific instructions provided by their prescribing physician or pharmacist. General guidance often advises taking the missed dose as soon as it is remembered, unless it is nearly time for the next scheduled dose. Do not take a double dose to make up for a missed one.

How to Store and Dispose of Орунгал?

Орунгал (itraconazole) has specific storage and disposal requirements defined by regulatory authorities to ensure product stability and environmental safety.

Storage Requirements

Itraconazole capsules must be stored at controlled room temperature, specifically between 15 C and 25 C (59 F and 77 F). They must be kept in the original blister packaging and protected from both moisture and light. The oral solution must not be frozen and is only stable for 30 days after the bottle is first opened. All forms must be stored out of the sight and reach of children.

Disposal Instructions

Expired or unused Орунгал must not be disposed of via wastewater or household waste. The proper procedure is to return any unused product to a pharmacist or a local pharmaceutical waste collection service.